NeurologyLive® Friday 5 — August 15, 2025

Author(s):

Key Takeaways

The July 2025 FDA update includes approvals, label updates, and a complete response letter, summarizing key regulatory actions in neurology.
AAIC 2025 provides groundbreaking insights into Alzheimer’s treatments and diagnostics through expert interviews and key takeaways.
Eric Siemers, MD, emphasizes the benefits of the p-tau 217 biomarker in improving Alzheimer’s disease screening accuracy and reducing patient burden.
Howard Fillit, MD, recaps notable developments in Alzheimer’s prevention, biomarkers, and therapeutics presented at AAIC 2025.
Sam Gandy, MD, PhD, discusses targeting amyloid-β oligomers with Valiltramiprosate, highlighting its potential role in Alzheimer’s disease therapy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 15, 2025.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, July 2025: Approval, Label Update, Complete Response Letter

Catch up on any of the neurology news headlines you may have missed over the course of July 2025, compiled all into 1 place by the NeurologyLive team.

2:AAIC 2025: Top Interviews and Key Takeaways

Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments and diagnostics.

3: Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]

4: NeuroVoices: Howard Fillit, MD, on AAIC 2025 Highlights in Alzheimer Disease Prevention, Biomarkers, and Therapeutics

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation recapped some of the notable recent developments in the Alzheimer disease field presented at the 2025 Alzheimer’s Association International Conference.

5: Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate

Sam Gandy, MD, PhD, director of the Center for Cognitive Health at the Icahn School of Medicine at Mount Sinai, discussed his presentation on detecting toxic amyloid-β oligomers and their role in AD pathology at AAIC 2025.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!